Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents

Area of Science:

• Oncology
• Immunotherapy
• Medicinal Chemistry

Background:

• Immune checkpoint inhibitors have transformed cancer treatment but face challenges with resistance and efficacy in certain cancers, such as triple-negative breast cancer.
• Acquired resistance leads to relapse in a significant portion of cancer patients, highlighting the need for novel therapeutic strategies.
• Combined immunotherapies present a promising approach to address these limitations and improve patient outcomes.

Purpose of the Study:

• To synthesize and characterize novel dual-action small-molecule conjugates targeting both PARP1 and PD-L1 pathways.
• To evaluate the in vitro anticancer efficacy and synergistic effects of these conjugates compared to individual agents.
• To elucidate the mechanistic basis of the conjugates' action on the PARP/PD-L1 axis and DNA repair pathways.

Main Methods:

• Synthesis and characterization of small-molecule PARP1/PD-L1 inhibitor conjugates.
• In vitro assessment of apoptosis and cytotoxic efficacy across various cancer cell lines.
• Chou-Talalay method for synergy analysis using combination indices.
• Apoptosis, cell cycle, immunoblotting, and T-cell proliferation assays to investigate mechanisms.

Main Results:

• The synthesized conjugates demonstrated significantly enhanced apoptosis and cytotoxic effects (2-20 fold) compared to individual PARP1 or PD-L1 inhibitors.
• Chou-Talalay analysis confirmed strong synergistic interactions between the PARP1 inhibitor (olaparib) and PD-L1 inhibitor (BMS-001) components.
• Mechanistic studies revealed the conjugates' impact on the PARP/PD-L1 axis, supporting their synergistic anticancer activity.

Conclusions:

• Dual-action small-molecule PARP1/PD-L1 inhibitor conjugates represent a novel class of targeted anticancer agents with superior efficacy.
• These conjugates offer a potential strategy to overcome resistance mechanisms in cancer, including triple-negative breast cancer.
• The findings pave the way for developing small-molecule immunochemotherapeutics and chemical probes to explore DNA repair and PD-L1 pathway cross-talk.